These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16989591)

  • 1. Future trends in human brucellosis treatment.
    Pappas G; Papadimitriou P; Christou L; Akritidis N
    Expert Opin Investig Drugs; 2006 Oct; 15(10):1141-9. PubMed ID: 16989591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic options for human brucellosis.
    Al-Tawfiq JA
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):109-20. PubMed ID: 18251668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical and biological factors in the control of Brucella and brucellosis.
    Gamazo C; Lecároz MC; Prior S; Vitas AI; Campanero MA; Irache JM; Blanco-Prieto MJ
    Curr Drug Deliv; 2006 Oct; 3(4):359-65. PubMed ID: 17076637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New approaches to the antibiotic treatment of brucellosis.
    Pappas G; Solera J; Akritidis N; Tsianos E
    Int J Antimicrob Agents; 2005 Aug; 26(2):101-5. PubMed ID: 16039098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective treatments in the management of brucellosis.
    Pappas G; Akritidis N; Tsianos E
    Expert Opin Pharmacother; 2005 Feb; 6(2):201-9. PubMed ID: 15757417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Brucella at the dawn of the third milenium: genomic organization and pathogenesis].
    Michaux-Charachon S; Foulongne V; O'Callaghan D; Ramuz M
    Pathol Biol (Paris); 2002 Jul; 50(6):401-12. PubMed ID: 12168259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of in vitro activities of tigecycline and various antibiotics against Brucella spp.
    Ozhak-Baysan B; Ongut G; Ogunc D; Gunseren F; Sepin-Ozen N; Ozturk F; Aktepe OC; Gultekin M
    Pol J Microbiol; 2010; 59(1):55-60. PubMed ID: 20568531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of some new antibiotics in treating experimental brucellosis].
    Maletskaia OV
    Antibiot Khimioter; 2002; 47(11):13-7. PubMed ID: 12698575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current therapeutical strategies in human brucellosis.
    Bosilkovski M; Keramat F; Arapović J
    Infection; 2021 Oct; 49(5):823-832. PubMed ID: 33650077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of brucella spondylitis: lessons from an impossible meta-analysis and initial report of efficacy of a fluoroquinolone-containing regimen.
    Pappas G; Seitaridis S; Akritidis N; Tsianos E
    Int J Antimicrob Agents; 2004 Nov; 24(5):502-7. PubMed ID: 15519485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modern chemotherapy for brucellosis in humans.
    Hall WH
    Rev Infect Dis; 1990; 12(6):1060-99. PubMed ID: 2267485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brucella melitensis bacteremia in children: review of 62 cases.
    Almuneef M; Memish ZA; Al Shaalan M; Al Banyan E; Al-Alola S; Balkhy HH
    J Chemother; 2003 Feb; 15(1):76-80. PubMed ID: 12678419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brucellosis in Sub-Saharan Africa: Current challenges for management, diagnosis and control.
    Ducrotoy M; Bertu WJ; Matope G; Cadmus S; Conde-Álvarez R; Gusi AM; Welburn S; Ocholi R; Blasco JM; Moriyón I
    Acta Trop; 2017 Jan; 165():179-193. PubMed ID: 26551794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study on antimicrobial susceptibility of Brucella in a city].
    Zuo SW; Ni ZL; Yao YB; Yang RS; Wang SK; Zhou YH
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2017 Dec; 35(12):939-941. PubMed ID: 29495161
    [No Abstract]   [Full Text] [Related]  

  • 15. Quinolones for brucellosis: treating old diseases with new drugs.
    Pappas G; Christou L; Akritidis N; Tsianos EV
    Clin Microbiol Infect; 2006 Sep; 12(9):823-5. PubMed ID: 16882286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orally administrable brucellosis vaccine: Brucella suis strain 2 vaccine.
    Xin X
    Vaccine; 1986 Dec; 4(4):212-6. PubMed ID: 3541425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virulence factors in brucellosis: implications for aetiopathogenesis and treatment.
    Fugier E; Pappas G; Gorvel JP
    Expert Rev Mol Med; 2007 Dec; 9(35):1-10. PubMed ID: 18088444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of Mexican brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis.
    López-Merino A; Contreras-Rodríguez A; Migranas-Ortiz R; Orrantia-Gradín R; Hernández-Oliva GM; Gutiérrez-Rubio AT; Cardeñosa O
    Scand J Infect Dis; 2004; 36(9):636-8. PubMed ID: 15370648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a multi-epitope peptide vaccine inducing robust T cell responses against brucellosis using immunoinformatics based approaches.
    Saadi M; Karkhah A; Nouri HR
    Infect Genet Evol; 2017 Jul; 51():227-234. PubMed ID: 28411163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of brucellosis by PCR and persistence after treatment in patients returning to the hospital for follow-up.
    Maas KS; Méndez M; Zavaleta M; Manrique J; Franco MP; Mulder M; Bonifacio N; Castañeda ML; Chacaltana J; Yagui E; Gilman RH; Guillen A; Blazes DL; Espinosa B; Hall E; Abdoel TH; Smits HL
    Am J Trop Med Hyg; 2007 Apr; 76(4):698-702. PubMed ID: 17426173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.